ChatGPT can provide inaccurate recommendations for cancer treatment
Robert Way
ChatGPT, which has been hyped since its introduction in 2022, failed to accurately provide cancer treatment recommendations that align with National Comprehensive Cancer Network (NCCN) guidelines.
A new study found that the language model-based chatbot, developed by OpenAI and part owned by Microsoft (NASDAQ:MSFT), made incorrect recommendations in one-third of cases.
Researchers at Boston's Brigham and Women's Hospital centered on breast, prostate, and lung cancer, and asked ChatGPT to provide a treatment plan based on the severity of each case. While 98% of ChatGPT's responses included at least one recommendation that met NCCN guidelines, complete agreement with them only happened 62% of the time.
Results also showed that in 12.5% of cases, ChatGPT offered recommendations not supported by the guidelines.
"The chatbot was most likely to mix in incorrect recommendations among correct ones, an error difficult even for experts to detect," the authors wrote in JAMA Oncology.
AI players: Alphabet (NASDAQ:GOOG), C3.ai (NYSE:AI), Meta Platforms (NASDAQ:META)
More on ChatGPT and AI

Will AI Transform The Healthcare Industry For Investors?
2 Stock Buys That Leverage ChatGPT And Generative AI
Google: Ignore The Noise, Its AI Is 3X Larger Than ChatGPT
The True Beneficiary Of ChatGPT Is C3.ai, Not Microsoft